Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,105 questions in 84 reviews · Metabolic and Endocrine Disorders
current versionsNo studies 434 · 39.3%Ungraded 32 · 2.9%Very low 246 · 22.3%Low 237 · 21.4%Moderate 132 · 11.9%High 24 · 2.2%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR Health‐related quality of life [measured by the validated questionnaire SF‐36] Radioiodine therapy versus antithyroid medications for Graves' disease (2016) · Cochrane | no estimate extracted | 2 studies · 425 participants | Ungraded |
Intervention NR Development and worsening of Graves' ophthalmopathy [examination by ophthalmologists] Radioiodine therapy versus antithyroid medications for Graves' disease (2016) · Cochrane | RR 1.94 [1.4, 2.7] | 2 studies · 417 participants | Low |
Intervention NR Individuals in euthyroid state [measured by serum thyroid hormone levels within the normal range] Radioiodine therapy versus antithyroid medications for Graves' disease (2016) · Cochrane | no estimate extracted | 1 study · 112 participants | Ungraded |
Intervention NR Recurrence of hyperthyroidism (relapse) [measured by serum thyroid hormone levels above the normal range after withdrawal of methimazole or end of radioiodine treatment] Radioiodine therapy versus antithyroid medications for Graves' disease (2016) · Cochrane | RR 0.2 [0.01, 2.66] | 2 studies · 417 participants | Very low |
Intervention NR Adverse events other than development or worsening of Graves' disease (a) Hypothyroidism [measured by TSH and/or thyroid hormones] (b) Drug reactions Radioiodine therapy versus antithyroid medications for Graves' disease (2016) · Cochrane | no estimate extracted | 1 study · 104 participants | Very low |
Intervention NR All‐cause mortality Radioiodine therapy versus antithyroid medications for Graves' disease (2016) · Cochrane | no estimate extracted | 2 studies · 425 participants | Ungraded |
Intervention NR Socioeconomic effects [costs per patient, based on the official hospital reimbursement system in Sweden] Radioiodine therapy versus antithyroid medications for Graves' disease (2016) · Cochrane | no estimate extracted | 1 study · 112 participants | Ungraded |
Subcutaneous insulin lispro vs intravenous regular insulin All‐cause mortality (N) Mean hospital stay: 2‐7 days Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis (2016) · Cochrane | no estimate extracted | 4 studies · 156 participants | Moderate |
Subcutaneous insulin aspart vs intravenous regular insulin Morbidity Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis (2016) · Cochrane | no estimate extracted | NR | No studies |
Subcutaneous insulin aspart vs intravenous regular insulin Adverse events other than hypoglycaemic episodes Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis (2016) · Cochrane | no estimate extracted | NR | No studies |
Subcutaneous insulin aspart vs intravenous regular insulin Time to resolution of diabetic ketoacidosis (h) Mean hospital stay: 3‐5 days Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis (2016) · Cochrane | no estimate extracted | 1 study · 30 participants | Very low |
Subcutaneous insulin aspart vs intravenous regular insulin Patient satisfaction Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis (2016) · Cochrane | no estimate extracted | NR | No studies |
Subcutaneous insulin aspart vs intravenous regular insulin Socioeconomic effects: length of hospital stay (days) Mean hospital stay: 3‐5 days Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis (2016) · Cochrane | no estimate extracted | 1 study · 30 participants | Low |
Subcutaneous insulin lispro vs intravenous regular insulin Hypoglycaemic episodes (N) Mean hospital stay: 2‐7 days Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis (2016) · Cochrane | RR 0.59 [0.23, 1.52] | 4 studies · 156 participants | Low |
Subcutaneous insulin lispro vs intravenous regular insulin Morbidity (N) Mean hospital stay: 2‐7 days Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis (2016) · Cochrane | no estimate extracted | 2 studies · 96 participants | Ungraded |
Subcutaneous insulin lispro vs intravenous regular insulin Adverse events other than hypoglycaemic episodes Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis (2016) · Cochrane | no estimate extracted | NR | No studies |
Subcutaneous insulin lispro vs intravenous regular insulin Time to resolution of diabetic ketoacidosis (h) Mean hospital stay: 2‐4 days Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis (2016) · Cochrane | no estimate extracted | 2 studies · 90 participants | Very low |
Subcutaneous insulin lispro vs intravenous regular insulin Patient satisfaction Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis (2016) · Cochrane | no estimate extracted | NR | No studies |
Subcutaneous insulin lispro vs intravenous regular insulin Socioeconomic effects: length of hospital stay (days) Mean hospital stay: 4‐7 days Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis (2016) · Cochrane | no estimate extracted | 2 studies · 90 participants | Low |
Subcutaneous insulin aspart vs intravenous regular insulin All‐cause mortality (N) Mean hospital stay: 3‐5 days Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis (2016) · Cochrane | no estimate extracted | 1 study · 45 participants | Low |
Subcutaneous insulin aspart vs intravenous regular insulin Hypoglycaemic episodes (N) Mean hospital stay: 3‐5 days Subcutaneous rapid‐acting insulin analogues for diabetic ketoacidosis (2016) · Cochrane | RR 1 [0.07, 14.55] | 1 study · 30 participants | Low |
Intervention NR Diabetes‐related complications · adults with type 2 diabetes and severe mental illness Self management interventions for type 2 diabetes in adult people with severe mental illness (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR All‐cause mortality · adults with type 2 diabetes and severe mental illness Self management interventions for type 2 diabetes in adult people with severe mental illness (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events · adults with type 2 diabetes and severe mental illness Self management interventions for type 2 diabetes in adult people with severe mental illness (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health‐related quality of life · adults with type 2 diabetes and severe mental illness Self management interventions for type 2 diabetes in adult people with severe mental illness (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Self care behaviours: physical activity (measured by total energy expenditure in kcal) · adults with type 2 diabetes and severe mental illness Self management interventions for type 2 diabetes in adult people with severe mental illness (2016) · Cochrane | no estimate extracted | 1 study · 52 participants | Very low |
Intervention NR HbA1c [%] · adults with type 2 diabetes and severe mental illness Self management interventions for type 2 diabetes in adult people with severe mental illness (2016) · Cochrane | no estimate extracted | 1 study · 52 participants | Very low |
Intervention NR Socioeconomic effects · adults with type 2 diabetes and severe mental illness Self management interventions for type 2 diabetes in adult people with severe mental illness (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Changes in BMI and body weight a. BMI z scorea [units] · preschool children (aged 0 to 6 years) with overweight or obesity Diet, physical activity, and behavioural interventions for the treatment of overweight or obesity in… (2016) · Cochrane | no estimate extracted | 4 studies · 202 participants | Low |
Intervention NR Health‐related quality of life and self esteem · preschool children (aged 0 to 6 years) with overweight or obesity Diet, physical activity, and behavioural interventions for the treatment of overweight or obesity in… (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR All‐cause mortality · preschool children (aged 0 to 6 years) with overweight or obesity Diet, physical activity, and behavioural interventions for the treatment of overweight or obesity in… (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Morbidity · preschool children (aged 0 to 6 years) with overweight or obesity Diet, physical activity, and behavioural interventions for the treatment of overweight or obesity in… (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Parent‐child relationship or assessment of parenting · preschool children (aged 0 to 6 years) with overweight or obesity Diet, physical activity, and behavioural interventions for the treatment of overweight or obesity in… (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Socioeconomic effects · preschool children (aged 0 to 6 years) with overweight or obesity Diet, physical activity, and behavioural interventions for the treatment of overweight or obesity in… (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events · preschool children (aged 0 to 6 years) with overweight or obesity Diet, physical activity, and behavioural interventions for the treatment of overweight or obesity in… (2016) · Cochrane | no estimate extracted | 1 study · 88 participants | Very low |
Intervention NR HrQoL and self esteem a. DUX 25 (Dutch Child AZL TNO Quality‐of‐Life tool: total score and 4 domains; scale 0 to 100; higher score indicates better HrQoL) · preschool children (aged 0 to 6 years) with overweight or obesity Diet, physical activity, and behavioural interventions for the treatment of overweight or obesity in… (2016) · Cochrane | no estimate extracted | 1 study · 40 participants | Very low |
Intervention NR All‐cause mortality · preschool children (aged 0 to 6 years) with overweight or obesity Diet, physical activity, and behavioural interventions for the treatment of overweight or obesity in… (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Morbidity · preschool children (aged 0 to 6 years) with overweight or obesity Diet, physical activity, and behavioural interventions for the treatment of overweight or obesity in… (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Parent‐child relationship or assessment of parenting (CFQ ‐ Child Feeding Questionnaire: 31 items) · preschool children (aged 0 to 6 years) with overweight or obesity Diet, physical activity, and behavioural interventions for the treatment of overweight or obesity in… (2016) · Cochrane | no estimate extracted | 2 studies · 44 participants | Very low |
Intervention NR Socioeconomic effects · preschool children (aged 0 to 6 years) with overweight or obesity Diet, physical activity, and behavioural interventions for the treatment of overweight or obesity in… (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Changes in BMI and body weight 1. Dairy‐rich diet a. BMI z score [units]a · preschool children (aged 0 to 6 years) with overweight or obesity Diet, physical activity, and behavioural interventions for the treatment of overweight or obesity in… (2016) · Cochrane | no estimate extracted | 1 study · 59 participants | Very low |
Intervention NR Adverse events · preschool children (aged 0 to 6 years) with overweight or obesity Diet, physical activity, and behavioural interventions for the treatment of overweight or obesity in… (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR All‐cause mortality · people at risk for the development of type 2 diabetes mellitus Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications… (2016) · Cochrane | no estimate extracted | 1 study · 274 participants | Very low |
Intervention NR Serious adverse events · people at risk for the development of type 2 diabetes mellitus Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications… (2016) · Cochrane | no estimate extracted | 1 study · 9306 participants | Moderate |
Intervention NR Cardiovascular mortality · people at risk for the development of type 2 diabetes mellitus Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications… (2016) · Cochrane | no estimate extracted | 1 study · 9306 participants | Moderate |
Intervention NR (a) Non‐fatal myocardial infarction (b) Non‐fatal stroke (c) Congestive heart failure · people at risk for the development of type 2 diabetes mellitus Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications… (2016) · Cochrane | no estimate extracted | 1 study · 9306 participants | Moderate |
Intervention NR Health‐related quality of life · people at risk for the development of type 2 diabetes mellitus Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications… (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Socioeconomic effects · people at risk for the development of type 2 diabetes mellitus Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications… (2016) · Cochrane | no estimate extracted | 1 study · 9306 participants | Ungraded |
Intervention NR Incidence of type 2 diabetes mellitus Measured as 2 consecutive fasting blood glucose values ≥ 6.1 mmol/L (NANSY 2011b) or no definition provided (Eriksson 2006) · people at risk for the development of type 2 diabetes mellitus Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications… (2016) · Cochrane | RR 0.75 [0.54, 1.04] | 2 studies · 307 participants | Very low |
Intervention NR Serious adverse events · people at risk for the development of type 2 diabetes mellitus Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications… (2016) · Cochrane | no estimate extracted | NR | No studies |